コンテンツへスキップ
Merck

PHR1631

Supelco

リスペリドン

Pharmaceutical Secondary Standard; Certified Reference Material

別名:

R 64,766

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C23H27FN4O2
CAS番号:
分子量:
410.48
MDL番号:
UNSPSCコード:
41116107
PubChem Substance ID:
NACRES:
NA.24

グレード

certified reference material
pharmaceutical secondary standard

品質水準

認証

traceable to BP 1137
traceable to Ph. Eur. R1000600
traceable to USP 1604654

APIファミリー

risperidone

CofA

current certificate can be downloaded

包装

pkg of 500 mg

テクニック

HPLC: suitable
gas chromatography (GC): suitable

アプリケーション

pharmaceutical (small molecule)

フォーマット

neat

保管温度

2-30°C

SMILES記法

CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1

InChI

1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3

InChI Key

RAPZEAPATHNIPO-UHFFFAOYSA-N

遺伝子情報

類似した製品をお探しですか? 訪問 製品比較ガイド

詳細

Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
Risperidone is a new central 5-hydroxytryptamine2 and dopamine D2 antagonist. It is used to treat agitation, aggression,and psychosis caused during demnetia. It is a neuroleptic drug. It is also an atypical antipsychotic drug which is used for treating schizophrenia.
Risperidone is a psychotropic agent, belonging to the chemical class of benzisoxazole derivatives and is commonly used for the treatment of schizophrenia.

アプリケーション

Risperidone may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using colorimetric technique and reversed-phase high-performance liquid chromatography technique.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

アナリシスノート

このような2次標準は、入手可能な場合にはUSP、EP、BPの1次標準にマルチトレーサビリティを提供します。

その他情報

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

脚注

To see an example of a Certificate of Analysis for this material enter LRAC2895 in the Documents slot below. This is an example certificate only and may not be the lot that you receive.

おすすめ製品

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

ピクトグラム

Skull and crossbones

シグナルワード

Danger

危険有害性情報

注意書き

危険有害性の分類

Acute Tox. 3 Oral

保管分類コード

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable


Choose from one of the most recent versions:

試験成績書(COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

RP-HPLC estimation of risperidone in tablet dosage forms
Baldania.LS, et al.
Indian Journal of Pharmaceutical Sciences, 70(4), 494-494 (2008)
A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Brodaty H
The Journal of Clinical Psychiatry, 64(2), 134-143 (2003)
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
Csernansky JG
The New England Journal of Medicine, 346(1), 16-22 (2002)
The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.
Kapur S
Life Sciences, 57(10), PL103-PL107 (1995)
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G
Journal of Clinical Psychopharmacology, 13(1), 25-40 (1993)

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)